Drugs / MSCTRAIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03298763 | Mar 2019 → Sep 2023 | lung adenocarcinoma | University College, London | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSCTRAIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03298763 ↗ |
| Modality | Cell therapy | “Mesenchymal stromal cells genetically modified to express TRAIL” NCT03298763 ↗ |
| Route | Intravenous | “MSCTRAIL, administered as an intravenous 60 minutes infusion” NCT03298763 ↗ |